Article Text

PDF
Research paper
Assessment of cancer risk with β-interferon treatment for multiple sclerosis
  1. Elaine Kingwell1,
  2. Charity Evans2,
  3. Feng Zhu1,
  4. Joel Oger1,
  5. Stanley Hashimoto1,
  6. Helen Tremlett1
  1. 1Faculty of Medicine Division of Neurology, Multiple Sclerosis Program University of British Columbia, Vancouver, British Columbia, Canada
  2. 2College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
  1. Correspondence to Dr Elaine Kingwell, Faculty of Medicine (Neurology), UBC Hospital, 2211 Wesbrook mall, University of British Columbia, Vancouver, British Columbia, Canada V6T 2B5; elainejk{at}mail.ubc.ca

Abstract

Objective The risk of cancer after exposure to the β-interferons (IFNβs) for multiple sclerosis (MS) has not been established. We assessed whether IFNβ treatment for MS is associated with cancer risk or the risk of specific cancers in a population-based observational study.

Methods The British Columbia MS database was linked to the provincial Cancer Registry, Vital Statistics death files and Health Registration files. Using a nested case-control design, MS cancer cases were matched with up to 20 randomly selected MS controls at the date of cancer diagnosis by sex, age (±5 years) and study entry year using incidence density sampling. Associations between treatment exposure and overall or specific (breast, colorectal, lung and prostate) cancers were estimated by conditional logistic regression, adjusted for MS disease duration and age. Tumour size at cancer diagnosis was compared between treated and untreated patients using the stratified Wilcoxon test to explore potential lead time bias.

Results The cohort included 5146 relapsing-onset MS patients and 48 705 person-years of follow-up, during which 227 cancers were diagnosed. Exposure to IFNβ was not significantly different for cases and controls (OR 1.28; 95% CI 0.87 to 1.88). There was a non-significant trend towards an increased risk of IFNβ exposure in the breast cancer cases (OR 1.77; 95% CI 0.92 to 3.42), but no evidence of a dose–response effect. Tumour size was similar between IFNβ treated and untreated cases.

Conclusions There was no evidence of an increased cancer risk with exposure to IFNβ over a 12-year observation period. However, the trend towards an association between IFNβ and breast cancer should be investigated further.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.